ARTICLE
|
doi:10.20944/preprints202308.0506.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
cemiplimab; pembrolizumab; immune checkpoint inhibitor; PD-1; cutaneous squamous cell carcinoma
Online: 7 August 2023 (10:37:53 CEST)